To homepage

Best Chemotherapy for lung cancer doctors in Turkey: TOP 14 doctors

Content meets the Bookimed Editorial Policy and is medically reviewed by

Fahad Mawlood

Yesim Yildirim

  • 4.6 Excellent 508 reviews
  • 22 years of experience
  • accreditations:
  • Turkey, Istanbul, Anadolu Medical Center
  • Professor Yildirim specializes in lung cancer immunotherapy and targeted therapies at Anadolu Medical Center, with over 80 international publications.

    • Member of ESMO and ESO, recognized for advanced oncology expertise
    • Author of chapters in 'Handbook of Advanced Cancer Care Treatment'
    • Professor at Halic University, teaching future oncologists
    • Special training in Melanoma and Kidney Cancer Clinic at Mount Vernon, London
  • Read more
Package price from
$10,450
Info

Eda Tanrikulu

  • 4.6 Excellent 508 reviews
  • 21 years of experience
  • Turkey, Istanbul, Anadolu Medical Center
  • Board-certified medical oncologist specializing in chemotherapy at Anadolu Medical Center. Dr. Tanrikulu ranks among Turkey's top specialists in the field.

    • Specialist in medical oncology with training from Marmara University
    • Ranked 3rd in Turkey for minor specialty exam in 2013
    • Conducted international clinical studies in oncology
    • Former head of medical oncology unit at Haydarpaşa Numune Hospital
  • Read more
Chemotherapy for lung cancer
$1,400 - $3,300
Info

Mustafa Solak

  • 4.6 Excellent 200 reviews
  • 20 years of experience
  • Turkey, Istanbul, Hisar Hospital Intercontinental
  • Specializes in chemotherapy for lung cancer, with training at Hacettepe University Cancer Institute and MD Anderson Cancer Center.

    • Residency at Istanbul Sisli Etfal Teaching and Research Hospital
    • Experienced in treating various cancers, including lung cancer
    • Fellowship training at one of the top cancer institutes
  • Read more
Doctor's visit
Price on request
Info

Mustafa Serkan Alemdar

  • 4.5 Good 6 reviews
  • 20 years of experience
  • Turkey, Antalya , Medical Park Antalya Hospital Complex
  • Dr. Alemdar specializes in medical oncology with a focus on lung cancer treatment at Medical Park Antalya Hospital Complex.

    • Board-certified in medical oncology since 2018
    • Over 15 years of experience in internal medicine and oncology
    • Trained at Akdeniz University – a leading medical institution in Turkey
    • Works with advanced chemotherapy protocols for lung cancer
  • Read more
Doctor's visit
Price on request
Info

Prof. Sezer Sağlam

  • 5 Excellent 1 review
  • 27 years of experience
  • Turkey, Istanbul, Gayrettepe Florence Nightingale Hospital
  • Prof. Sezer Sağlam specializes in medical oncology with extensive experience in gastrointestinal and lung cancer treatments at Gayrettepe Florence Nightingale Hospital.

    • Professor of Medical Oncology since 2016
    • Fellowship-trained at Istanbul University, one of Turkey's top medical schools
    • Member of ESMO and ASCO – leading oncology associations
    • Over 15 years in medical oncology practice
  • Read more
Doctor's visit
Price on request
Info

Tahsin Ozatli

  • 4.4 Good 17 reviews
  • 2016 years of experience
  • Turkey, Istanbul, Istinye University Liv Hospital Bahcesehir
  • Associate Professor Ozatli specializes in complex lung cancer cases at Istinye University Liv Hospital Bahcesehir.

    • Over 15 years of experience in oncology
    • Specializes in breast, lung, and gastrointestinal cancers
    • Trained at Selcuk University's Faculty of Medicine
    • Previously worked at Ankara Oncology Clinic
  • Read more
Chemotherapy for lung cancer
$2,000 - $2,000
Info

Find out about the best doctors here

20 top ranked Chemotherapy for lung cancer doctors in the world are represented on this page. The list includes only verified specialists known for their experience and high success rates.

The ranking is composed according to the Bookimed patient reviews and considers the rating of hospitals where doctors practice.

Top 5 Chemotherapy for lung cancer doctors on Bookimed.com:

How to choose the best Chemotherapy for lung cancer doctors in the world?

The specialist’s CV contains details about the doctor’s expertise and work experience, education, scientific research, and languages spoken. Compare information on several specialists, read carefully about their experience, success rates, and methods they apply. Make sure the chosen doctor has relevant experience in the treatment of a medical issue you are looking for. Read reviews of patients who had a consultation with the chosen specialist.

Famous Chemotherapy for lung cancer doctors have vast experience, continue education constantly, participate in professional associations and have positive feedback from patients treated.

What is the cost of a doctor's consultation?

The price for the consultation on Chemotherapy for lung cancer varies between experts and depends on certain factors, such as:

  • the country of practicing
  • the clinical experience and reputation
  • the medical degree and educational background
  • the doctor’s workload
  • medical developments, proprietary techniques used, and awards, if any.

How to make an appointment with a chosen doctor?

To schedule your visit, just submit a request on Bookimed.com. Our coordinator will contact you to discuss the time and details of the appointment, so everything will go smoothly.

We can help to find the right doctors for Chemotherapy for lung cancer if you have any difficulties with a choice. Bookimed services are free for patients ♥

Where you go for medical treatment

Ercan Ozden

  • 5 Excellent 1 review
  • 27 years of experience
  • Turkey, Istanbul, VM Medical Park Pendik Hospital
  • Specialized in medical oncology with 20+ years of experience – Dr. Ozden focuses on personalized lung cancer treatment.

    • Trained at Istanbul University's Cerrahpaşa Faculty of Medicine
    • Medical oncology subspecialty from Kocaeli University
    • Served as an internal medicine specialist for 12 years
    • Currently practices at VM Medical Park Pendik Hospital
  • Read more
Doctor's visit
Price on request
Info

Irfan Cicin

  • New
  • 29 years of experience
  • Turkey, Istanbul, İstinye University Liv Hospital Topkapı
  • Professor Cicin brings over 20 years of specialized experience in medical oncology, focusing on lung cancer treatment at İstinye University Liv Hospital Topkapı.

    • Fellowship-trained in medical oncology at Trakya University
    • Professor at Trakya University Faculty of Medicine
    • Extensive experience in chemotherapy protocols
    • Military hospital background adds unique perspective
  • Read more
Doctor's visit
Price on request
Info

Muhammed Mustafa Atci

  • New
  • 15 years of experience
  • Turkey, Istanbul, İstinye University Liv Hospital Topkapı
  • Associate Professor of Medical Oncology at İstinye University Liv Hospital Topkapı, with extensive research and clinical expertise in lung cancer treatment.

    • Member of the American Society of Clinical Oncology (ASCO) since 2018
    • Published multiple studies on lung cancer outcomes and treatment efficacy
    • Specializes in personalized chemotherapy protocols for lung cancer patients
  • Read more
Doctor's visit
Price on request
Info

Atakan Topcu

  • 5 Excellent 3 reviews
  • 13 years of experience
  • Turkey, Istanbul, Medipol Acibadem District Hospital
  • Assoc. Prof. Atakan Topcu specializes in lung cancer and has published over 50 scientific articles on oncology and geriatric care.

    • Expert in targeted therapies and immunotherapy for solid tumors
    • Member of European Society for Medical Oncology (ESMO)
    • Fellowship-trained in Medical Oncology at Bezmialem Vakıf University
    • Focuses on cancer-related malnutrition and geriatric oncology
  • Read more
Doctor's visit
Price on request
Info

Dr. Sezer Saglam

  • 5 Excellent 51 reviews
  • 29 years of experience
  • accreditations:
  • Turkey, Istanbul, Istanbul Florence Nightingale Hospital
  • Prof. Dr. Sezer Sağlam is a medical oncologist at Gayrettepe Florence Nightingale Hospital. He specializes in gastrointestinal and breast cancers. He has contributed to cancer care through research, especially with his study on the best timing for surgery after neoadjuvant therapy in rectal cancer. This work has influenced global treatment protocols.

    Dr. Sağlam has led clinical trials in targeted therapies and precision medicine. His research on liver-transplanted patients with hepatocellular carcinoma was nominated for the 2024 International Best Researcher Award. He is a member of ASCO, ESMO, and ENET. Dr. Sağlam provides personalized and evidence-based oncology care.

  • Read more
Doctor's visit
Price on request
Info

Muhammed Gomec

  • 5 Excellent 1 review
  • 17 years of experience
  • Turkey, Sivas, Medicana Sivas Hospital
Doctor's visit
Price on request
Info

Abdullah Sakin

  • 4.5 Good 2 reviews
  • 19 years of experience
  • Turkey, Istanbul, Medipol Bahçelievler Hospital
  • Assoc. Prof. Abdullah Sakin leads the Medical Oncology Department at Medipol Bahçelievler Hospital with a focus on lung cancer treatments.

    • Over a decade of experience in medical oncology
    • Specialized training at Istanbul Okmeydanı Training and Research Hospital
    • Former head of Medical Oncology at Yüzüncü Yıl University
    • Works with advanced chemotherapy protocols
  • Read more
Doctor's visit
Price on request
Info

Nail Paksoy

  • 4.5 Good 2 reviews
  • 15 years of experience
  • accreditation:
  • Turkey, Istanbul, Medipol Bahçelievler Hospital

  • PROFESSIONAL EXPERIENCE

    2011-2012
    Erzurum Koprukoyu State Hospital
    Department: General Medicine

    2012-2017
    Istanbul University Cerrahpaşa Medical Faculty
    Department: Internal Medicine

    06/2017-10/2017
    Istanbul Gaziosmanpasa Taksim Training and Research Hospital
    Department: Internal Medicine

    10/2017-11/2018
    Istanbul University Istanbul Medical Faculty
    Department: Allergy and Immunology Fellowship

    2018/2022
    Istanbul University Oncology Institute
    Department: Medical Oncology Fellowship

    2022-2023
    Tekirdag City Hospital
    Department: Medical Oncology Specialist

    2023-present
    Istanbul Medipol University Medipol Bahcelievler Private Hospital
    Department: Medical Oncology Assoc. Prof.

     

    EDUCATION

    2005-2011
    Medical Education
    Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey

    2012-2017
    Internal Medicine
    Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey

    2017-2018
    Allergy-Immunology Fellowship
    Istanbul University Istanbul Medical Faculty
    Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey

    2018-2022
    Medical Oncology Fellowship
    Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey

    2022
    ESMO Board Certification in Medical Oncology
    10th September 2022 in Paris, France.

    2023
    Medical Oncology Assoc. Prof.
    Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey

     

    INTERNATIONAL CLINICAL TRIALS:

    1. Astefania - ROCHE

    • Title: A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
    • Role: Subinvestigator

    2. PFİZER

    • Title: A Study Of Lorlatinib Versus Crizotinib In First-Line Treatment Of Patients With ALK-Positive NSCLC
    • Role: Subinvestigator

    3. RECITE - AMGEN

    • Title: Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
    • Role: Subinvestigator

    4. NAVIGATE - BAYER

    • Title: A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
    • Role: Subinvestigator

    5. RUBY - Tesaro (PRA)

    • Title: A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer
    • Role: Subinvestigator

    6. ENGOT-ov43/GOG-3036 - MSD

    • Title: Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK001/ENGOT-ov43/GOG-3036)
    • Role: Subinvestigator

    7. ASTRA ZENECA

    • Title: To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
    • Role: Subinvestigator

    8. ROSY-O - ASTRA ZENECA

    • Title: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
    • Role: Subinvestigator
    •  

    INTERNATIONAL PUBLICATIONS

    I. Published journal articles indexed by SCI, SSCI, and AHCI

    Weekly Paclitaxel in Classic Kaposi Sarcoma

    • Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Ahmed, M. A., Karaman, S., & Aydiner, A.
    • Journal: Medicine, 102(5)

    Carboplatin Desensitization in Ovarian Carcinoma

    • Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Yildiz, A., Ak, N., & Aydiner, A.
    • Journal: Medicine, 101(45), e31726

    High-Dose Chemotherapy for Ewing’s Sarcoma

    • Authors: Paksoy, N., Ferhatoglu, F., Dogan, İ., Khanmammadov, N., Celik, A. I., Gulbas, Z., & Başaran, M.
    • Journal: Medicine, 101(49), e32213

    Multidrug Refractory TFE3(+) Renal Cell Carcinoma

    • Authors: Paksoy, Nail, et al.
    • Journal: Journal of Oncology Pharmacy Practice, 2022, 28.1: 215-221

    Crizotinib Efficacy in NSCLC with MET Alterations

    • Authors: Gürbüz, M., Kiliçkap, S., Bilici, A., Karadurmuş, N., Sezer, A., Şendur, M. A. N., ... & Demirkazik, A.
    • Journal: Medicine, 101(50), e32368

    Clinicopathological Features in ALK Mutant NSCLC

    • Authors: Dogan, I., Gurbuz, M., Paksoy, N., Ferhatoglu, F., Vatansever, S., Saip, P., ... & Aydiner, A.
    • Journal: Medicine, 101(34)

    PSMA-Based Tumor Burden in Prostate Cancer

    • Authors: HAS SIMSEK, Duygu, et al.
    • Journal: Annals of Nuclear Medicine, 2021, 35.6: 680-690

    Atezolizumab in Metastatic Urothelial Carcinoma

    • Authors: TURAL, Deniz, et al.
    • Journal: European Urology Focus, 2021, 7.5: 1061-1066

    Pulmonary Sarcomatoid Carcinoma

    • Authors: FERHATOGLU, Ferhat, et al.
    • Journal: Oncology Research and Treatment, 2021, 44.11: 590-601

    Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma

    • Authors: TURAL, Deniz, et al.
    • Journal: International Journal of Clinical Oncology, 2021, 26.8: 1506-1513

    Atezolizumab with Chemotherapy in Small Cell Lung Cancer

    • Authors: GÜRBÜZ, Mustafa, et al.
    • Journal: Journal of Cancer Research and Clinical Oncology, 2022, 1-9

    FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer

    • Authors: AY, Seval, et al.
    • Journal: Journal of Chemotherapy, 2022, 1-7

    Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients

    • Authors: CIL, Ibrahim, et al.
    • Journal: Tumori Journal, 2022, 108.1: 19-25

    Real-Life Efficacy of Osimertinib in Advanced NSCLC

    • Authors: HIZAL, Mutlu, et al.
    • Journal: Journal of Cancer Research and Clinical Oncology, 2022, 148.6: 1501-1508

    ALK-Positive Cells Percentage and Alectinib Efficacy

    • Authors: Hizal, M., Bilgin, B., Paksoy, N., Atcı, M. M., Kahraman, S., Kılıçkap, S., ... & Şendur, M. A. N.
    • Journal: Journal of Cancer Research and Clinical Oncology, 149(8), 4141-4148

    Real-World Data on Alectinib in ALK-Positive NSCLC

    • Authors: Hizal, M., Bilgin, B., Paksoy, N., Kılıçkap, S., Atcı, M. M., Kahraman, S., ... & Şendur, M. A. N.
    • Journal: Future Oncology, 18(23), 2573-2582

    Prognostic Factors in Metastatic RCC with T790M Mutation

    • Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
    • Journal: Journal of Cancer Research and Therapeutics

    FLOT Regimen in Metastatic Gastric Cancer

    • Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
    • Journal: Journal of Cancer Research and Therapeutics

    Desensitization Protocol in Lenalidomide Hypersensitivity Reactions

    • Authors: DEMIR, Semra, et al.
    • Journal: Annals of Allergy, Asthma & Immunology, 2019, 123.4: 394-397

    Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity

    • Authors: ÖZDEMIR, Seçil Kepil, et al.
    • Journal: Allergy, 2019, 74.6: 1187-1190

    Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors

    • Authors: Ünal, Ç., Azizy, A., Karabulut, S., Taştekin, D., Akyıldız, A., Yaşar, S., ... & Sağlam, S.
    • Journal: The Oncologist, oyad257

    Subsequent Treatments in Hormone-Positive Breast Cancer Progression

    • Authors: Karacin, C., Oksuzoglu, B., Demirci, A., Keskinkılıç, M., Baytemür, N. K., Yılmaz, F., ... & Hacıbekiroğlu, İ.
    • Journal: BMC cancer, 23(1), 192

    Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer

    • Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Saip, P., & Aydiner, A.
    • Journal: Scientific Reports, 13(1), 8779

    Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer

    • Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Ferhatoğlu, F., Ak, N., ... & Aydiner, A.
    • Journal: Journal of Cancer Research and Clinical Oncology, 1-9

    Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer

    • Authors: Doğan, İ., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydıner, A.
    • Journal: European Journal of Breast Health, 19(2), 128

    Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer

    • Authors: Kahraman, S., Erul, E., Seyyar, M., Gumusay, O., Bayram, E., Demirel, B. C., ... & Nahit Sendur, M. A.
    • Journal: Future Oncology, 19(10), 727-736

    Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients

    • Authors: Dogan, I., Paksoy, N., & Basaran, M.
    • Journal: Journal of Cancer Research and Therapeutics

    Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients

    • Authors: Dogan, I., Paksoy, N., & Basaran, M.
    • Journal: Journal of Cancer Research and Therapeutics

    Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases

    • Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
    • Journal: Journal of Cancer Research and Therapeutics

    FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer

    • Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
    • Journal: Journal of Cancer Research and Therapeutics

    Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer

    • Authors: Erol, C., Sakin, A., Basoglu, T., Ozden, E., Cabuk, D., Dogan, M., ... & Sendur, M. A. N.
    • Journal: [Not specified]

    Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi Sarcoma

    • Authors: Khanmammadov, N., Paksoy, N., Doğan, I., Ferhatoğlu, F., Saip, P., & Aydiner, A.
    • Journal: Medicine, 102(39), e35383

    Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma

    • Authors: Pehlivan, M., Paksoy, N., Aydin, E., Basaran, M., & Ekenel, M.
    • Journal: Medicine, 102(41), e35245

    Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)

    Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)

    Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.

    Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49

    Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4

    Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.

    Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY

    Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of Pulmonology

    Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)

    Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)

    Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)

    Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)

    Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye

     

    Thesis:

    Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)

    International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)

    Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination

    • Authors: Dogan, I., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydiner, A. (2022)

    Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study

    • Authors: Şenocak Taşçi, E., Oyan, B., Sonmez, O., Mutlu, A. U., Atcı, M. M., Oner, I., ... & Gulmez, A. (2022)

    Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer

    • Authors: Dogan, I., Aydin, E., Paksoy, N., Ferhatoglu, F., Ak, N., Ibis, K., ... & Aydiner, A. (2021)

    Efficacy of temozolomide in pretreated patients with metastatic sarcoma

    • Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

    Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors

    • Authors: Ferhatoglu, F., Paksoy, N., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M. (2021)

    Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma

    • Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

    Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases

    • Authors: Dogan, İ., Iribas, A., Paksoy, N., Ekenel, M., Vatansever, S., & Basaran, M. (2021)

    Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma

    • Authors: Tural, D., Olmez, O. F., Sümbül, A. T., Artac, M., Ozhan, N., Akar, E., ... & Erman, M. (2021)

    Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study

    • Authors: Esin, E., Ahmed, M. A., Yıldırım, H. Ç., Mandel, N. M., Erdemoglu, E., Sari, M., ... & Paydas, S. (2023)

    Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences

    • Authors: Tural, D., Ölmez, Ö. F., Sümbül, A. T., Artaç, M., Özhan, N., Akar, E., ... & Kılıçkap, S. (2021)

     

     

  • Read more
Doctor's visit
Price on request
Info

Choosing Right Doctor and Clinic: Insider Tips

When selecting a doctor or clinic, keep these key points in mind:
Check credentials
Verify certifications from bodies like ISAPS, JCI, etc.
Review success rates
Choose doctors with solid experience in your specific treatment.
Read patient reviews
Browse Bookimed reviews from real patients to learn about their experiences.
Ensure effective communication
Pick clinics that offer language support for a smooth treatment process.
Ask about services
Confirm if they provide accommodation and transfers, and check the costs.
Choosing a clinic abroad can be stressful. At Bookimed, with over 800K patients helped, we understand your concerns. We know how to find trusted doctors, the best price-quality options, and solutions for even complex cases. We’re here to guide you every step of the way.
Yan Matsiivskiy
Head of Medical Coordinator Team

Bookimed Insights: Top Chemotherapy for lung cancer Specialists in Turkey

Bookimed has coordinated 4 requests for Chemotherapy for lung cancer in Turkey, working with 14 specialists. The doctors in this table consistently stand out for their credentials and expertise in addressing specific patient needs. All information comes from actual patient cases and treatment offers created by our partner clinics.
DoctorexperienceGood Fit ForWhat Sets Them ApartClinic & LocationConsultation
22 years of experienceLung cancer immunotherapySpecializes in cutting-edge lung cancer treatments like immunotherapy and targeted therapies. ESMO-certified professor with 80+ publications and international training.
Turkey
from $250
21 years of experienceLung cancer chemotherapyBoard-certified medical oncologist ranked among Turkey's top specialists. Conducted international clinical studies and leads Anadolu Medical Center's chemotherapy program.
Turkey
from $160
20 years of experienceLung cancer chemotherapyTrained at Hacettepe University Cancer Institute and MD Anderson. Specializes in lung cancer treatments, including chemotherapy for complex cases.
Turkey
from $100
20 years of experienceLung cancer chemotherapySpecializes in lung cancer chemotherapy with advanced protocols. Board-certified in medical oncology and trained at Akdeniz University.
Turkey
Price on request
27 years of experienceLung cancer chemotherapySpecializes in lung cancer with proven expertise in chemotherapy protocols. Professor of Medical Oncology and member of ESMO & ASCO.
Turkey
Price on request
2016 years of experienceComplex lung cancer casesSpecializes in challenging lung cancer treatments with 15+ years in oncology. Associate Professor trained at Selcuk University. Experienced in premier Turkish hospitals.
Turkey
Price on request
27 years of experiencePersonalized lung cancer treatmentExpert in tailoring chemotherapy plans for lung cancer patients. Combined 20+ years of internal medicine and medical oncology expertise.
Turkey
Price on request
29 years of experienceLung cancer chemotherapyProfessor of Medical Oncology with fellowship training. Combines academic expertise with clinical practice at a leading university hospital.
Turkey
Price on request
15 years of experiencePersonalized lung cancer chemotherapySpecializes in tailored chemotherapy protocols for lung cancer with published research on treatment efficacy. ASCO member and academic leader in medical oncology.
Turkey
Price on request
13 years of experienceGeriatric lung cancer casesSpecializes in geriatric oncology and lung cancer – published key research on sarcopenia in lung cancer patients. ESMO member with fellowship training.
Turkey
Price on request